bluuebunny/crossref_metadata_2025_split huggingface dataset:
Improving reconciliation following medical injury: a qualitative study of responses to patient safety incidents in New Zealand
Authors: Moore Jennifer , Mello Michelle M 
Published: March 2017

BackgroundDespite the investment in exploring patient-centred alternatives to medical malpractice in New Zealand (NZ), the UK and the USA, patients' experiences with these processes are not well understood. We sought to explore factors that facilitate and impede reconciliation following patient safety incidents and identify recommendations for strengthening institution-led alternatives to malpractice litigation.MethodsWe conducted semistructured interviews with 62 patients injured by healthcare in NZ, administrators of 12 public hospitals, 5 lawyers specialising in Accident Compensation Corporation (ACC) claims and 3 ACC staff. NZ was chosen as the research site because it has replaced medical malpractice litigation with a no-fault scheme. Thematic analysis was used to identify key themes from interview transcripts.ResultsInterview responses converged on five elements of the reconciliation process that were important: (1) ask, rather than assume, what patients and families need from the process and recognise that, for many patients, being heard is important and should occur early in the reconciliation process; (2) support timely, sincere, culturally appropriate and meaningful apologies, avoiding forced or tokenistic quasi-apologies; (3) choose words that promote reconciliation; (4) include the people who patients want involved in the reconciliation discussion, including practitioners involved in the harm event; and (5) engage the support of lawyers and patient relations staff as appropriate.DiscussionPolicymakers and healthcare institutions are keenly interested in non-litigation approaches to resolving malpractice incidents. Interviewing participants involved in patient safety incident reconciliation processes suggests that healthcare institutions should not view apology as a substitute for other remedial actions; use flexible guidelines that distil best-practice principles, ensuring that steps are not missed, while not prescribing a ‘one size fits all’ communication approach.
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
Authors: Parseghian Christine M. , Parikh Nila U. , Wu Ji Yuan , Jiang Zhi-Qin , Henderson Laura , Tian Feng , Pastor Brice , Ychou Marc , Raghav Kanwal , Dasari Arvind , Fogelman David R. , Katsiampoura Anastasia D. , Menter David G. , Wolff Robert A. , Eng Cathy , Overman Michael J. , Thierry Alain R. , Gallick Gary E. , Kopetz Scott 
Published: March 2017

Abstract
Purpose: Aberrant activation of the intracellular tyrosine kinase Src has been implicated as a mechanism of acquired chemotherapy resistance in metastatic colorectal cancer (mCRC). Here, the oral tyrosine kinase Src inhibitor, dasatinib, was investigated in combination with FOLFOX and cetuximab.
Experimental Design: We performed a phase IB/II study of 77 patients with previously treated mCRC. Primary objectives were to determine the maximum tolerated dose, dose-limiting toxicities (DLT), pharmacodynamics, and efficacy. Using a 3 + 3 design, patients received FOLFOX6 with cetuximab and escalating doses of dasatinib (100, 150, 200 mg daily), followed by a 12-patient expansion cohort at 150 mg. Phase II studies evaluated FOLFOX plus dasatinib 100 mg in KRAS c12/13mut patients or in combination with cetuximab if KRAS c12/13WT. FAK and paxillin were utilized as surrogate blood biomarkers of Src inhibition, and paired biopsies of liver metastases were obtained in patients in the expansion cohort.
Results: In phase IB, the DLTs were grade 3/4 fatigue (20%) and neutropenia (23%). In phase II, grade 3/4 fatigue (23%) and pleural effusions (11%) were present. Response rates were 20% (6 of 30) in the phase IB escalation and expansion cohort and 13% (3 of 24) and 0% (0 of 23) in the KRAS c12/13WT and mutant cohorts of phase II, respectively. Median progression-free survival was 4.6, 2.3, and 2.3 months, respectively. There was no evidence of Src inhibition based on surrogate blood biomarkers or paired tumor biopsies.
Conclusions: The combination of dasatinib plus FOLFOX with or without cetuximab showed only modest clinical activity in refractory colorectal cancer. This appears to be primarily due to a failure to fully inhibit Src at the achievable doses of dasatinib. The combination of dasatinib plus FOLFOX with or without cetuximab did not show meaningful clinical activity in refractory colorectal cancer due to failure to fully inhibit Src. Clin Cancer Res; 23(15); 4146–54. ©2017 AACR.
Increased blood pressures in veterans with post traumatic stress disorder
Authors: Moazen-Zadeh Ehsan , Khoshdel Alireza , Avakh Farhad , Rahmani Arash 
Published: March 2017

Objective Veterans of war affected by posttraumatic stress disorder (PTSD) are at increased risk for cardiovascular diseases. We aimed to compare brachial and central blood pressures between veterans with PTSD and controls. Method In this case-control study on veterans of Iran–Iraq war, 50 veterans with PTSD and 50 veterans as controls were selected from an outpatient clinic and matched for age ±3 years. Exclusion criteria were malignancies, severe anatomical defects such as amputated extremities, history of PTSD before serving in war, comorbid psychiatric disorders other than anxiety or depressive disorders. Detailed history was taken concerning medical and social aspects. Beck Depression Inventory was used for depressive symptoms. Brachial blood pressures were measured using both auscultatory and oscillometric devices. Measures of central hemodynamics were estimated accordingly. Data on lipid profile were collected either through medical records or newly required lab tests. Results Brachial systolic, diastolic, and pulse pressures as well as estimated central systolic and diastolic pressures were significantly higher in the PTSD group. Beck Depression Inventory scores, frequency of diabetes mellitus, and hypertension were significantly higher in the PTSD group. PTSD status was an independent predictor of both brachial and central systolic and diastolic pressures. Conclusions We demonstrated increased measures of blood pressure in veterans with PTSD independent of depression and other risk factors. Further research is warranted to confirm our results.
Comparison of mammography, ultrasound, and MRI in size assessment of ductal carcinoma in situ with histopathologic correlation
Authors: Baek Soo Heui , Choi Woo Jung , Cha Joo Hee , Kim Hak Hee , Shin Hee Jung , Chae Eun Young 
Published: March 2017

Background The ability to accurately assess tumor size in ductal carcinoma in situ (DCIS) is an important clinical issue when selecting the appropriate treatment plan. Purpose To compare the accuracy of using mammography, ultrasound (US), and magnetic resonance imaging (MRI) to assess DCIS tumor size based on imaging and histopathological findings. Material and Methods Fifty-six patients with DCIS were included. Mammography, US, and MRI were reviewed, and the accuracy of the measured tumor sizes were compared with the imaging and histopathological parameters. Results If visible, tumor measurements demonstrated high reliability with the pathologically determined size, with the best results obtained using US ( k = 0.851) followed by mammography ( k = 0.815) and MRI ( k = 0.738). Tumor size assessment was significantly more accurate when the lesion was shown as a mass on US ( P = 0.003) or MRI ( P < 0.001) with minimal and mild background parenchymal enhancement ( P = 0.016) on MRI. When mammography was used to assess tumor size, the tumors with positive estrogen receptor status and luminal A subtype demonstrated a significantly more accurate tumor size. Conclusion The combination of US and MRI, in addition to mammography, has an important role in assessing the exact tumor extent of DCIS.
Religiosity and Health Through the Decades: Is There a Gender Difference?
Authors: Mukerjee Swati , Venugopal Arun 
Published: March 2017

Purpose: An empirical examination of the long-term association, disaggregated by gender, between religiosity and self-rated health with reference to demographic shifts in labor force participation, education, and income. Design: General Social Survey data. Setting: United States, 1974 to 2012. Participants: A total of 23 353 respondents. Measures: Self-assessed health; 2 key religiosity variables: attendance and intensity of belief; income, labor market variables, education, standard demographic variables, household size, region, and time dummies. Analysis: Probit estimation conducted for the aggregate sample by gender as well as by decades to examine possible gender differential changes over time. Results: Attendance has declined overall with a much greater decline for women. The overall positive association between religiosity and health masks considerable heterogeneity across gender and time; higher and stable for males, there is no longer a significant association for females. Increased education, income, and labor force participation can explain only part of this association. Education is the strongest mediator. Conclusion: The way women and men benefit from religious attendance has changed, suggesting that some pathways may be working differently for women now, especially those with less education. Moving away from church networks could be due to a perceived lack of support or substitution by other social networks. Ceteris paribus, since religious participation has been shown to weaken preference for risky consumption, declining participation, especially for women, may show up as an increase in risky behavior.
Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system
Authors: Rashid Nazia , Koh Han A , Lin Kathy J , Stwalley Brian , Felber Eugene 
Published: March 2017

Purpose To evaluate treatment patterns in patients diagnosed with incident chronic myelogenous leukemia (CML) newly initiating therapy with imatinib, dasatinib, or nilotinib. Patients were followed to determine switching and discontinuation rates. Factors associated with switching or discontinuation from index TKI therapy, reasons for discontinuation based on electronic chart notes, and frequency of laboratory monitoring were assessed during the follow-up period. Methods A retrospective cohort study was conducted in chronic myelogenous leukemia patients aged ≥ 18 years who were identified from the Kaiser Permanente Southern California (KPSC) Cancer Registry database during the study time period of 1 January 2007 to 12 December 2013. The index date was defined as the date of the first TKI prescription (imatinib, dasatinib, or nilotinib) identified during the study time period with no prior history of TKI use within 12 months. Patients had to have continuous membership with drug benefit eligibility and no prior history of stem cell transplant (SCT) or other cancers during the 12 months prior to the index date. Baseline characteristics were identified during 12 months prior to the index date and outcomes were identified during the follow-up period after the index date. All patients were followed from index TKI therapy until end of study time period (12 December 2014), death, stem cell transplant, or disenrollment from the health plan unless one of the following occurred first: a patient switched their index therapy, or a patient discontinued their index therapy. Forward stepwise selection multivariable logistic regression models were used to evaluate factors associated with patients who continued therapy compared to those who switched or discontinued therapy with the index TKI. Chart notes were reviewed 30 days prior and 30 days post index TKI discontinuation to evaluate reasons for discontinuation. Molecular and cytogenetic testing frequency was also assessed during the follow-up period among the different patient groups. Results Two hundred sixteen patients were identified with incident chronic myelogenous leukemia and use of TKI therapy: 189 (87.5%) received imatinib, 19 (8.8%) received dasatinib, and 8 (3.7%) received nilotinib. The mean age on index date was 53 years and 63% were male; 103 patients (48%) continued on their index therapy, while 62 patients (28%) switched, and 51 patients (24%) discontinued.
Dosimetric Comparison and Evaluation of 4 Stereotactic Body Radiotherapy Techniques for the Treatment of Prostate Cancer
Authors: Seppälä Jan , Suilamo Sami , Tenhunen Mikko , Sailas Liisa , Virsunen Heli , Kaleva Erna , Keyriläinen Jani 
Published: March 2017

Purpose: The aim of this study was to compare dosimetric characteristics, monitor unit, and delivery efficiency of 4 different stereotactic body radiotherapy techniques for the treatment of prostate cancer. Methods: This study included 8 patients with localized prostate cancer. Dosimetric assets of 4 delivery techniques for stereotactic body radiotherapy were evaluated: robotic CyberKnife, noncoplanar intensity-modulated radiotherapy, and 2 intensity-modulated arc therapy techniques (RapidArc and Elekta volumetric-modulated arc therapy). All the plans had equal treatment margins and a prescription dose of 35 Gy in 5 fractions. Results: Statistically significant differences were observed in homogeneity index and mean doses of bladder wall and penile bulb, all of which were highest with CyberKnife. No significant differences were observed in the mean doses of rectum, with values of 15.2 ± 2.6, 13.3 ± 2.6, 13.1 ± 2.8, and 13.8 ± 1.6 Gy with CyberKnife, RapidArc, volumetric-modulated arc therapy, and noncoplanar intensity-modulated radiotherapy, respectively. The highest dose conformity was realized with RapidArc. The dose coverage of the planning target volume was lowest with noncoplanar intensity-modulated radiotherapy. Treatment times and number of monitor units were largest with CyberKnife (on average 34.0 ± 5.0 minutes and 8704 ± 1449 monitor units) and least with intensity-modulated arc therapy techniques (on average 5.1 ± 1.1 minutes and 2270 ± 497 monitor units). Conclusion: Compared to CyberKnife, the RapidArc, volumetric-modulated arc therapy, and noncoplanar intensity-modulated radiotherapy produced treatment plans with similar dosimetric quality, with RapidArc achieving the highest dose conformity. Overall, the dosimetric differences between the studied techniques were marginal, and thus, the choice of the technique should rather focus on the delivery accuracies and dose delivery times.
Lucchesiite, CaFe2+3Al6(Si6O18)(BO3)3(OH)3O, a new mineral species of the tourmaline supergroup
Authors: Bosi Ferdinando , Skogby Henrik , Ciriotti Marco E. , Gadas Petr , Novák Milan , Cempírek Jan , Všianský Dalibor , Filip Jan 
Published: March 2017

AbstractLucchesiite, CaFe32+Al6(Si6O18)(BO3)3(OH)3O, is a new mineral of the tourmaline supergroup. It occurs in the Ratnapura District, Sri Lanka (6°35'N, 80°35'E), most probably from pegmatites and in Mirošov near Strážek, western Moravia, Czech Republic, (49°27'49.38"N, 16°9'54.34"E) in anatectic pegmatite contaminated by host calc-silicate rock. Crystals are black with a vitreous lustre, conchoidal fracture and grey streak. Lucchesiite has a Mohs hardnessof ∼7 and a calculated density of 3.209 g/cm3(Sri Lanka) to 3.243 g/cm3(Czech Republic). In plane-polarized light, lucchesiite is pleochroic (O = very dark brown and E = light brown) and uniaxial (–). Lucchesiite is rhombohedral, space groupR3m,a≈ 16.00 Å,c≈ 7.21 Å,V≈ 1599.9 Å3,Z= 3. The crystal structure of lucchesiite was refined toR1 ≈ 1.5% using ∼2000 unique reflections collected with MoKα X-ray intensity data. Crystal-chemical analysis for the Sri Lanka (holotype) and Czech Republic (cotype) samples resulted in the empirical formulae, respectively:X(Ca0.69Na0.30K0.02)∑1.01Y(Fe1.442+Mg0.72Al0.48Ti0.334+V0.023+Mn0.013+Zn0.01)∑3.00Z(Al4.74Mg1.01Fe0.253+)∑6.00[T(Si5.85Al0.15)∑6.00O18](BO3)3V(OH)3W[O0.69F0.24(OH)0.07]∑1.00andX(Ca0.49Na0.45□0.05K0.01)∑1.00Y(Fe1.142+Fe0.953+Mg0.42Al0.37Mn0.03Ti0.084+Zn0.01)∑3.00Z(Al5.11Fe0.383+Mg0.52)∑6.00[T(Si5.88Al0.12)∑6.00O18](BO3)3V[(OH)2.66O0.34]∑3.00W(O0.94F0.06)∑1.00.Lucchesiite is an oxy-species belonging to the calcic group of the tourmaline supergroup. The closest end-member composition of a valid tourmaline species is that of feruvite, to which lucchesiite is ideally related by the heterovalent coupled substitutionZAl3++O1O2–↔ZMg2++O1(OH)1–. The new mineral was approved by the International Mineralogical Association Commission on New Minerals, Nomenclature and Classification (IMA 2015-043).
Odigitriaite, CsNa5Ca5[Si14B2O38]F2, a new caesium borosilicate mineral from the Darai-Pioz alkaline massif, Tajikistan: Description and crystal structure
Authors: Agakhanov Atali A. , Pautov Leonid A. , Sokolova Elena , Hawthorne Frank C. , Yu Karpenko Vladimir , Siidra Oleg I. , Muftakhov Vyacheslav A. 
Published: March 2017

AbstractOdigitriaite, a new Cs, Na, Ca borosilicate mineral, was discovered in moraine adjacent to the Darai-Pioz alkaline massif in the upper reaches of the Darai-Pioz river at the intersection of the Turkestansky, Zeravshansky and Alaisky mountain ridges, Tajikistan. It occurs as irregular thin flakes associated with quartz, pectolite, baratovite, fluorite, pekovite, polylithionite, aegirine, leucosphenite, pyrochlore, neptunite, reedmergnerite, mendeleevite-(Ce), zeravshanite and sokolovaite. It is colourless with a white streak, is translucent and has a vitreous lustre; it does not fluoresce under ultraviolet light. Odigitriaite is brittle with an uneven fracture and a Mohs hardness of 5. The calculated density is 2.80(2) g/cm3. The indices of refraction are α = 1.502, β = 1.564, γ = 1.576; 2Vobs = 46(2)°, dispersion is weak r > v, and there is no pleochroism. The chemical composition is as follows (electron microprobe, H2O calculated from structure): SiO2 55.30, Al2O3 0.09, Y2O3 0.44, MnO 0.94, FeO 0.10, PbO 0.21, K2O 0.01 Cs2O 8.36, B2O3 4.75, H2O 0.37, F 1.74, O = F2 –0.74, total 99.43 wt.%. The empirical formula of odigitriaite is Cs0.90Na5.12Ca4.68Mn0.20Y0.06Fe0.02Pb0.01[Si13.92Al0.03B2.06O38]F1.39(OH)0.62. The end-member formula is CsNa5Ca5[Si14B2O38]F2. The strong reflections in the powder X-ray diffraction pattern are: [(d, Å), (I, %), (hkl)]: 5.45 (25) (1 1 3), 4.66 (33) (3 1 1), 4.40 (26) (0 2 2), 4.10 (36) (3 1 3), 3.95 (25) (3̄ 1 3), 2.85 (31) (2 2 2), 2.68 (40) (0 0 6), 3.62 (45) (0 2 4), 3.35 (100) (2̄ 2 4), 3.31 (30) (3̄ 1 5), 3.25 (35) (4 0 4), 3.04 (60) (4̄ 2 2), 2.925 (22) (4̄ 2 3), 1.813 (23) (9 1 0). Odigitriaite is monoclinic, space group C2/c, a = 16.652(5), b = 9.598 (3), c = 22.120(7) Å, β= 92.875(14)°, V = 3530.9(1.9) Å3, Z = 4. The crystal structure of odigitriaite was solved by direct methods and refined to an R1 value of 2.75% based on single-crystal X-ray data. It is a double-layer sheet-borosilicate mineral; Cs and Na are intercalated within the double-layer sheet, and the double layers are linked by interstitial Ca and Na atoms.
Dyrnaesite-(La) a new hyperagpaitic mineral from the Ilímaussaq alkaline complex, South Greenland
Authors: Rønsbo Jørn G. , Balić-Žunić Tonči , Petersen Ole V. 
Published: March 2017

AbstractThe new mineral, dyrnaesite-(La), is found in the Ilímaussaq alkaline complex, South Greenland. The holotype material originates from an arfvedsonite lujavrite sheet as an accessory mineral. Dyrnaesite-(La) is pale yellowish green, with no cleavage and an irregular fracture. Density is 3.68(2)/3.682 g/cm3(measured/ calculated). It is biaxial, negative, 2Vα = 47(1)/48 (measured/calculated); α = 1.6226(5), β = 1.6852(10), γ = 1.6982(2);X=c,Y=a,Z=b. The average values of microprobe analyses are (wt.%) P2O537.17, SiO20.15, CaO 0.90, Na2O 20.06, La2O316.44, CeO220.23, Pr2O31.40, Nd2O33.47, Sm2O30.24, Dy2O30.06, Y2O30.06.The crystal structure was solved from single-crystal X-ray diffraction data. Dyrnaesite-(La) is orthorhombic,Pnma;a= 18.4662(7) Å,b= 16.0106(5) Å,c= 7.0274(2) Å,V= 2077.7(2) Å3,Z= 4. The structural formula calculated from the diffraction data and microprobe analysis is Na7.89(Ce0.94Ca0.06)∑1.00(Ca0.12La1.14Ce0.40Pr0.10Nd0.24)∑2.00(PO4)6, the simplified formula is Na8Ce4+REE2(PO4)6. The crystal structure is related closely to that of vitusite-(Ce), but is distinct from it in several aspects. The five strongest lines of the powder X-ray diffraction pattern are (d Å, (I %), (hkl)); 6.57 (100) (101), 4.62 (40) (301, 230, 400), 3.50 (40) (331), 2.80 (86) (232, 402), 2.67 (54) (060,630).
Joanneumite, Cu(C3N3O3H2)2(NH3)2, a new mineral from Pabellón de Pica, Chile and the crystal structure of its synthetic analogue
Authors: Bojar Hans-Peter , Walter Franz , Baumgartner Judith 
Published: March 2017

AbstractThe new mineral joanneumite was found at Pabellón de Pica Mountain, Iquique Province, Tarapacá Region, Chile, where it occurs as violet microcrystalline aggregates up to 2 mm in size in small cracks in a gabbroic rock, which is covered by a guano deposit. Associated minerals are salammoniac, dittmarite, möhnite and gypsum. Joanneumite is non-fluorescent and the Mohs hardness is 1. The calculated density is 2.020 g cm–3. The infrared spectrum of joanneumite shows the frequencies of NH3and isocyanurate groups and the absence of absorptions of H2O molecules and OH–ions. The chemical composition (electron microprobe data, the hydrogen was calculated from the structural formula, wt.%) is C 20.33, N 31.11, O 28.34, Cu 17.27, Zn 0.24, H 2.82, total 100.11. The empirical formula is Cu0.96Zn0.01N7.84C5.98O6.25H9.96and the idealized formula is CuN8C6O6H10with the structural formula Cu(C3N3O3H2)2(NH3)2. Due to the lack of suitable single crystals the synthetic analogue of joanneumite was prepared for the single-crystal structure refinement. The crystal structure was solved and refined toR= 0.025 based upon 1166 unique reflections withI> 2σ (I). Joanneumite is triclinic, space groupP1̄,a= 4.982(1),b= 6.896(1),c= 9.115(2) Å, α = 90.53(3), β = 97.85(3), γ = 110.08(3)°,V= 290.8(1) Å3,Z= 1 obtained from single-crystal data at 100 K, which are in good agreement with cell parameters from powder diffraction data of joanneumite at 293 K:a= 5.042(1),b= 6.997(1),c= 9.099(2) Å, α = 90.05(3), β = 98.11(2), γ = 110.95(3)° andV= 296.3(1) Å3. The eight strongest lines of the powder X-ray diffraction pattern are [d, Å (I,%) (hkl)] 6.52 (68) (010), 5.15 (47) (011), 4.66 (21) (100, 110), 4.35 (9) (1̄11), 3.29 (6) (1̄20), 3.22 (7) (1̄1̄1), 3.140 (100) (1̄21), 2.074 (7) (1̄32). The crystal structure of joanneumite is identical with the structure of synthetic bis(isocyanurato) diamminecopper(II).